File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Contractile effect of endothelin in human placental veins: Role of endothelium prostaglandins and thromboxane

TitleContractile effect of endothelin in human placental veins: Role of endothelium prostaglandins and thromboxane
Authors
Issue Date1993
PublisherMosby, Inc. The Journal's web site is located at http://www.elsevier.com/locate/ajog
Citation
American Journal Of Obstetrics And Gynecology, 1993, v. 169 n. 4, p. 919-924 How to Cite?
AbstractObjective: The aim was to study the effects of endothelin-1 on human placental veins and the role of cyclooxygenase products as mediators of these effects. Study design: Rings of placental veins with and without endothelium were suspended in organ chambers filled with physiologic salt solution. After a period of stabilization at optimal basal tension, isometric tensions in the control group were recorded at increasing concentrations of endothelin-1 (10-10 to 10-7 mol/L). Rings in the experimental groups were treated with either indomethacin (cyclooxygenase inhibitor, 10-5 mol/L), dazoxiben (thromboxane synthetase inhibitor, 10-4 mol/L), or SQ29548 (thromboxane receptor antagonist 10-6 mol/L) before addition of endothelin-1. To demonstrate the presence of functional thromboxane receptors in the rings, contractile responses to U-46619 (10-9 to 10-6 mol/L), a thromboxane A2 analog were measured. The effectiveness of SQ29548 blockade was tested in rings treated with SQ29548 (10-6 mol/L) before addition of U-46619. The concentration-response curves of the treated and control groups were compared with the Student paired t test. Results: Endothelin-1 in doses of 10-10 to 10-7 mol/L caused concentration-dependent contraction of placental veins. Indomethacin significantly reduced the response of veins with endothelium to low endothelin-1 concentrations (10-9.5 to 10-9 mol/L), (p < 0.05). However, it had no effect at higher endothelin-1 concentrations or in vessels without endothelium. The presence of functional thromboxane A2 receptors was confirmed by the vasoconstrictor effect of U-46619 and its blockade by treatment with SQ29548. Neither SQ29548 nor the thromboxane A2 synthesis inhibitor dazoxiben significantly influenced the response to endothelin-1. Conclusions: These results demonstrated that endothelin-1 is a potent vasoconstrictor in the human placental vein. Although functional thromboxane A2 receptors exist in this vessel, endothelin-1 is action is independent of thromboxane A2. Prostaglandins may mediate part of the endothelin-1-induced placental vasoconstriction. However, endothelin-1 acts primarily by a direct effect on vascular smooth muscle cells.
Persistent Identifierhttp://hdl.handle.net/10722/171099
ISSN
2015 Impact Factor: 4.681
2015 SCImago Journal Rankings: 2.255
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLe, SQen_US
dc.contributor.authorWasserstrum, Nen_US
dc.contributor.authorMombouli, JVen_US
dc.contributor.authorVanhoutte, PMen_US
dc.date.accessioned2012-10-30T06:12:11Z-
dc.date.available2012-10-30T06:12:11Z-
dc.date.issued1993en_US
dc.identifier.citationAmerican Journal Of Obstetrics And Gynecology, 1993, v. 169 n. 4, p. 919-924en_US
dc.identifier.issn0002-9378en_US
dc.identifier.urihttp://hdl.handle.net/10722/171099-
dc.description.abstractObjective: The aim was to study the effects of endothelin-1 on human placental veins and the role of cyclooxygenase products as mediators of these effects. Study design: Rings of placental veins with and without endothelium were suspended in organ chambers filled with physiologic salt solution. After a period of stabilization at optimal basal tension, isometric tensions in the control group were recorded at increasing concentrations of endothelin-1 (10-10 to 10-7 mol/L). Rings in the experimental groups were treated with either indomethacin (cyclooxygenase inhibitor, 10-5 mol/L), dazoxiben (thromboxane synthetase inhibitor, 10-4 mol/L), or SQ29548 (thromboxane receptor antagonist 10-6 mol/L) before addition of endothelin-1. To demonstrate the presence of functional thromboxane receptors in the rings, contractile responses to U-46619 (10-9 to 10-6 mol/L), a thromboxane A2 analog were measured. The effectiveness of SQ29548 blockade was tested in rings treated with SQ29548 (10-6 mol/L) before addition of U-46619. The concentration-response curves of the treated and control groups were compared with the Student paired t test. Results: Endothelin-1 in doses of 10-10 to 10-7 mol/L caused concentration-dependent contraction of placental veins. Indomethacin significantly reduced the response of veins with endothelium to low endothelin-1 concentrations (10-9.5 to 10-9 mol/L), (p < 0.05). However, it had no effect at higher endothelin-1 concentrations or in vessels without endothelium. The presence of functional thromboxane A2 receptors was confirmed by the vasoconstrictor effect of U-46619 and its blockade by treatment with SQ29548. Neither SQ29548 nor the thromboxane A2 synthesis inhibitor dazoxiben significantly influenced the response to endothelin-1. Conclusions: These results demonstrated that endothelin-1 is a potent vasoconstrictor in the human placental vein. Although functional thromboxane A2 receptors exist in this vessel, endothelin-1 is action is independent of thromboxane A2. Prostaglandins may mediate part of the endothelin-1-induced placental vasoconstriction. However, endothelin-1 acts primarily by a direct effect on vascular smooth muscle cells.en_US
dc.languageengen_US
dc.publisherMosby, Inc. The Journal's web site is located at http://www.elsevier.com/locate/ajogen_US
dc.relation.ispartofAmerican Journal of Obstetrics and Gynecologyen_US
dc.subject.mesh15-Hydroxy-11 Alpha,9 Alpha-(Epoxymethano)Prosta-5,13-Dienoic Aciden_US
dc.subject.meshAdulten_US
dc.subject.meshEndothelins - Pharmacologyen_US
dc.subject.meshEndothelium, Vascular - Drug Effects - Physiologyen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshHydrazines - Pharmacologyen_US
dc.subject.meshImidazoles - Pharmacologyen_US
dc.subject.meshIndomethacin - Pharmacologyen_US
dc.subject.meshPlacenta - Blood Supplyen_US
dc.subject.meshPregnancyen_US
dc.subject.meshProstaglandin Endoperoxides, Synthetic - Pharmacologyen_US
dc.subject.meshProstaglandin-Endoperoxide Synthases - Physiologyen_US
dc.subject.meshProstaglandins - Pharmacologyen_US
dc.subject.meshThromboxane A2 - Antagonists & Inhibitors - Physiologyen_US
dc.subject.meshThromboxane-A Synthase - Antagonists & Inhibitorsen_US
dc.subject.meshVasoconstriction - Drug Effectsen_US
dc.subject.meshVasoconstrictor Agents - Pharmacologyen_US
dc.subject.meshVeinsen_US
dc.titleContractile effect of endothelin in human placental veins: Role of endothelium prostaglandins and thromboxaneen_US
dc.typeArticleen_US
dc.identifier.emailVanhoutte, PM:vanhoutt@hku.hken_US
dc.identifier.authorityVanhoutte, PM=rp00238en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/0002-9378(93)90027-G-
dc.identifier.pmid8238149-
dc.identifier.scopuseid_2-s2.0-0027376874en_US
dc.identifier.volume169en_US
dc.identifier.issue4en_US
dc.identifier.spage919en_US
dc.identifier.epage924en_US
dc.identifier.isiWOS:A1993MC45800026-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridLe, SQ=7006184502en_US
dc.identifier.scopusauthoridWasserstrum, N=7004673923en_US
dc.identifier.scopusauthoridMombouli, JV=7004285772en_US
dc.identifier.scopusauthoridVanhoutte, PM=7202304247en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats